InVitae Corp (NVTA) Holdings Increased by Royal Bank of Canada

Royal Bank of Canada grew its holdings in shares of InVitae Corp (NASDAQ:NVTA) by 131.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,631 shares of the medical research company’s stock after buying an additional 71,892 shares during the period. Royal Bank of Canada owned 0.29% of InVitae Corp worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Verity Asset Management Inc. lifted its holdings in InVitae Corp by 0.8% during the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock worth $101,000 after buying an additional 81 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in InVitae Corp by 21.1% during the 1st quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after buying an additional 2,987 shares during the last quarter. Donald L. Hagan LLC lifted its holdings in InVitae Corp by 30.0% during the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after buying an additional 3,000 shares during the last quarter. American International Group Inc. lifted its holdings in InVitae Corp by 31.3% during the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares during the last quarter. Finally, Credit Suisse AG lifted its holdings in InVitae Corp by 22.9% during the 1st quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock worth $279,000 after buying an additional 4,694 shares during the last quarter.

A number of analysts have recently commented on NVTA shares. Zacks Investment Research cut InVitae Corp from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. BidaskClub upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $15.00 target price (up previously from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $13.50.

InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.37). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/11/03/invitae-corp-nvta-holdings-increased-by-royal-bank-of-canada.html.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

What are top analysts saying about InVitae Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for InVitae Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit